Using the Right Criteria for MCAS

Curr Allergy Asthma Rep. 2024 Feb;24(2):39-51. doi: 10.1007/s11882-024-01126-0. Epub 2024 Jan 20.

Abstract

Purpose of review: The current article aims to provide a comprehensive update on diagnostic criteria for mast cell activation syndrome (MCAS), addressing challenges in diagnosing and classifying MCAS and its variants.

Recent findings: In recent years, there has been a significant increase in our knowledge regarding the underlying mechanisms responsible for the activation of mast cells (MCs) in various pathological conditions. Furthermore, a set of criteria and a classification for MCASs have been established. MCAS is characterized by the presence of typical clinical symptoms, a substantial elevation in serum tryptase levels during an attack compared to the patient's baseline tryptase levels, and a response to MC mediator-targeting therapy. In this report, a thorough examination was conducted on the contemporary literature relating to MCAS, with a focus on comparing the specificity, sensitivity, and robustness of MCAS-related parameters within proposals for diagnosing and classifying MCAS and its variants. Moreover, the significance of employing specific consensus criteria in the assessment and categorization of MCAS in individual patients was underscored, due to the escalating occurrence of patients receiving a misdiagnosis of MCAS based on nonspecific criteria.

Keywords: Anaphylaxis; Hereditary alpha-tryptasemia; MCAS; Mast cell activation; Mastocytosis; Tryptase.

Publication types

  • Review

MeSH terms

  • Diagnosis, Differential
  • Humans
  • Mast Cell Activation Syndrome*
  • Mast Cells
  • Mastocytosis*
  • Tryptases

Substances

  • Tryptases